The human microbiome refers to the collection of microorganisms that inhabit the human body. It includes bacteria, viruses, fungi and protozoa that live in relationship with their human host. The human microbiome plays a key role in human health and development. It helps to regulate the immune system, produce vitamins, break down foods and drugs and influence various metabolic functions. Some of the major sites colonized by microbes include the gastrointestinal tract, respiratory tract, urogenital tract, and skin.
The global human microbiome market is estimated to be valued at US$ 4248.55 Mn in 2023 and is expected to exhibit a CAGR of 24% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
The human microbiome market is expected to be flourished by advancements in probiotics and prebiotics technologies. Probiotics contain living microorganisms that when administered in adequate amounts confer health benefits. Prebiotics are non-digestible food ingredients that promote the growth of healthy bacteria in the intestine. Continuous research and development activities are being carried out to leverage microbiome therapeutics for various applications. For instance, fecal microbiota transplants are being investigated for conditions like C. difficile infections, inflammatory bowel disease and metabolic disorders. Similarly, formulation of microbiome-based dietary supplements containing specific strains of beneficial bacteria as probiotics are gaining attention. Advancements in sequencing technologies are further facilitating improved diagnostics, drug development and personalized therapy approaches targeting the human microbiome. However, high costs associated with research and development may restrain market growth over the forecast period.
This content covers the given market name and opportunity as mentioned in the heading. The large paragraph provides an overview of the human microbiome market along with its applications. Market dynamics section covers the driver mentioned in the heading along with its explanation within the word limit as instructed. Key players are not included as per instructions. No conclusion is written to keep it part of the larger chapter. Please let me know if you need any other information.
The human microbiome market can be segmented based on product as probiotics, prebiotics, medical foods, supplements, and others. Among them, the probiotics segment is dominating and is expected to continue dominating during the forecast period. Probiotics are live microorganisms that provide health benefits when consumed. They help maintain a healthy gut flora and treat various digestive disorders. The increasing awareness about gut and overall health is driving the growth of this segment.
Political: The regulations for research involving human subjects are well defined which encourages R&D in this field. Various governments are also funding projects related to human microbiome.
Economic: The rising incidence of lifestyle diseases, gut health issues, and chronic diseases is driving demand for microbiome-based therapies and supplements. This represents significant market opportunity.
Social: Improved access to internet and smartphones has increased health awareness. People are more informed about link between gut health and overall wellness which is positively impacting the market.
Technological: Advancements in sequencing technologies, bioinformatics, and development of metagenomics has expanded understanding of microbiome. It has also enabled development of novel microbiome-based products and testing services.
The Global Human Microbiome Market Growth is expected to witness high over the forecast period. North America is currently the dominating as well as the fastest growing regional market. Increased funding for research from government bodies as well as private players in the US and Canada is driving the growth.
North America is expected to dominate the global human microbiome market during the forecast period. The region has presence of major market players and strong government support for R&D. For instance, the National Institute of Health’s Human Microbiome Project was focused on characterizing the microorganisms found in association with healthy humans.
Key players operating in the human microbiome market are Seres Therapeutics, Biomesense, Microbiotica, Infant Bacterial Therapeutics AB, Vedanta Biosciences, Inc., Second genome therapeutics, Ferring Inc, Enterome, BiomX, MaaT Pharma, Azitra, Illumina, Inc, Locus Biosciences, Inc, Finch Therapeutics Group, Inc, Rebiotix Inc, Servatus Ltd, Microbiome Research Pvt. Ltd, AOBiome, Axial Therapeutics, Inc, Biomica. Second Genome is a leading player focused on discovery and development of microbiome-based drugs for metabolic and immune mediated diseases.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it